At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed May 8, 2026 at 08:30 ET
CG Oncology reported Q1 2026 results with a net loss of $0.71 per share, slightly wider than the $0.45 loss a year ago, but the headline is the BLA completion timeline for cretostimogene in BCG-unresponsive NMIBC now guided to Q4 2026, with Phase 3 PIVOT-006 topline data expected in H1 2026. The company raised $391.4M via ATM in Q1, boosting cash to $1.1B, sufficient through 2029, and reported first commercial revenue of $1.07M. The stock will move on the BLA timeline clarity and upcoming PIVOT-006 data readout.
- BLA completion for cretostimogene in HR BCG-unresponsive NMIBC guided to Q4 2026 (previously no specific timeline)
- Phase 3 PIVOT-006 topline data in intermediate-risk NMIBC expected H1 2026
- First results from CORE-008 Cohort CX (cretostimogene + gemcitabine) to be presented at AUA May 16, 2026
- Net loss of $60.2M ($0.71/share) vs $34.5M ($0.45/share) in Q1 2025
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access